Embattled Mylan Quietly Generates Hundreds of Millions of Cash From This Non-Pharmaceutical Offering

Published: Jun 21, 2017

Mylan N.V. is best known for producing EpiPen emergency allergy treatments and generic drugs.

But a non-pharmaceutical offering – refined coal – has quietly generated hundreds of millions of dollars of tax credits for the company over the last six years that have boosted its bottom line, according to a Reuters review of company filings.

Since 2011, Mylan has bought 99 percent stakes in five companies across the U.S. that own plants which process coal to reduce smog-causing emissions.

Back to news